

type of report	<b>Current report</b>
number	73/2013
company	PHARMENA

**Meeting of the representatives of clinical centres which take part in phase II clinical trials over 1-MNA medicinal product**

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13<sup>th</sup> April 2012) and the communication on the progress in clinical trials over innovative anti-atherosclerosis medicinal product 1-MNA (published in current report no. 71/2013 of 10<sup>th</sup> October 2013), the Management Board of PHARMENA S.A. informs, that a training session for people responsible for conducting the trials in the selected research centres will take place in Montreal on 23-24 October 2013. The meeting's objective will consist in providing information on the programme and timetable of the intended clinical trials. This will constitute the final stage of preparations to the study's recruitment processes.

The aim of the phase II clinical trial over the 1-MNA anti-atherosclerosis medicinal product will consist in establishing the effective dose of the medicinal product and confirming the lack of side effects in humans in the tested doses. Planned time scope for the trial is 12 months from the date of obtaining permission from Health Canada market regulator. The supervisory institution will be Montreal Heart Institute, and participation of ca. 15 clinics in the trial is planned.

Montreal Heart Institute is a leading research centre in Canada, specialising in cardiology, and one of the largest institutes of this type in the world. It is a world renown Institute, that has introduced many innovatory solutions nationally and world-wide. For more information see [www.icm-mhi.org](http://www.icm-mhi.org).

Phase II clinical trials ("Proof of Concept") will be financed from funds raised from the issue of series D shares. Subsequent current reports issued by the Company will inform on progress of research and trials of the 1-MNA innovative anti-atherosclerotic medicinal product.

This information is made public due to the fact that conducting phase II clinical trial is necessary for commercialisation of 1-MNA anti-atherosclerotic medicinal product project, while potential revenues on the medicinal product commercialisation may have very significant impact on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

**Representatives of the company:**

- Konrad Palka – President of the Board
- Marzena Wiczorkowska – Vice President of the Board